Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease. 2017

Zhipei Sang, and Wanli Pan, and Keren Wang, and Qinge Ma, and Lintao Yu, and Yan Yang, and Ping Bai, and Chaoliang Leng, and Qian Xu, and Xiaoqing Li, and Zhenghuai Tan, and Wenmin Liu
College of Chemistry and Pharmaceutical Engineering, Nanyang Normal University, Nanyang, 473061, China. Electronic address: sangzhipei@126.com.

A series of novel ferulic acid-O-alkylamines derivatives were designed, synthesized, and evaluated as multitarget-directed ligands against Alzheimer's disease. In vitro studies displayed that all the synthesized target compounds showed impressive inhibitory activity against butyrylcholinesterase (BuChE), significant inhibition/disaggregation of self-induced β-amyloid (Aβ) aggregation and acted as potential antioxidants. Particularly, compound 7f, one of the most potent BuChE inhibitor (IC50 value of 0.021 μM for equine serum BuChE, 8.63 μM for ratBuChE and 0.07 μM for human serum BuChE), was found to be a good acetylcholinesterase (AChE) inhibitor (IC50 = 2.13 μM for electric eel AChE, 1.8 μM for ratAChE and 3.82 μM for human erythrocytes AChE), and the result of molecular docking provided an explanation for its selective BuChE inhibitory activity. Compound 7f also had noteworthy inhibitory effects on self-induced Aβ1-42 aggregation (50.8 ± 0.82%) and was found to disaggregate self-induced Aβ1-42 aggregation (38.7 ± 0.65%), which was further elucidated by the transmission electron microscopy. Meanwhile, compound 7f showed the modest antioxidant activity (0.55 eq of Trolox), good protective effect against H2O2-induced PC12 cell injury, with low toxicity. Moreover, compound 7f could cross the blood-brain barrier (BBB) in vitro. Significantly, compound 7f did not exhibit any acute toxicity in mice at doses up to 1000 mg/kg, and the step-down passive avoidance test showed this compound significantly reversed scopolamine-induced memory deficit in mice. Taken together, the results indicated that compound 7f is a very promising multifunctional agent in the treatment of Alzheimer's disease, particularly the advanced stages of AD.

UI MeSH Term Description Entries
D008569 Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions. Memory Loss,Age-Related Memory Disorders,Memory Deficits,Memory Disorder, Semantic,Memory Disorder, Spatial,Memory Disorders, Age-Related,Retention Disorders, Cognitive,Semantic Memory Disorder,Spatial Memory Disorder,Age Related Memory Disorders,Age-Related Memory Disorder,Cognitive Retention Disorder,Cognitive Retention Disorders,Deficit, Memory,Deficits, Memory,Memory Deficit,Memory Disorder,Memory Disorder, Age-Related,Memory Disorders, Age Related,Memory Disorders, Semantic,Memory Disorders, Spatial,Memory Losses,Retention Disorder, Cognitive,Semantic Memory Disorders,Spatial Memory Disorders
D001812 Blood-Brain Barrier Specialized non-fenestrated tightly-joined ENDOTHELIAL CELLS with TIGHT JUNCTIONS that form a transport barrier for certain substances between the cerebral capillaries and the BRAIN tissue. Brain-Blood Barrier,Hemato-Encephalic Barrier,Barrier, Blood-Brain,Barrier, Brain-Blood,Barrier, Hemato-Encephalic,Barriers, Blood-Brain,Barriers, Brain-Blood,Barriers, Hemato-Encephalic,Blood Brain Barrier,Blood-Brain Barriers,Brain Blood Barrier,Brain-Blood Barriers,Hemato Encephalic Barrier,Hemato-Encephalic Barriers
D002091 Butyrylcholinesterase An aspect of cholinesterase (EC 3.1.1.8). Pseudocholinesterase,Benzoylcholinesterase,Butyrylthiocholinesterase
D002800 Cholinesterase Inhibitors Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors
D003373 Coumaric Acids Hydroxycinnamic acid and its derivatives. Act as activators of the indoleacetic acid oxidizing system, thereby producing a decrease in the endogenous level of bound indoleacetic acid in plants. Coumaric Acid,Hydroxycinnamic Acid,Hydroxycinnamic Acids,Acid, Coumaric,Acid, Hydroxycinnamic,Acids, Coumaric,Acids, Hydroxycinnamic
D004524 Eels Common name for an order (Anguilliformes) of voracious, elongate, snakelike teleost fishes. Anguilliformes,Eel
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000975 Antioxidants Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. Anti-Oxidant,Antioxidant,Antioxidant Activity,Endogenous Antioxidant,Endogenous Antioxidants,Anti-Oxidant Effect,Anti-Oxidant Effects,Anti-Oxidants,Antioxidant Effect,Antioxidant Effects,Activity, Antioxidant,Anti Oxidant,Anti Oxidant Effect,Anti Oxidant Effects,Anti Oxidants,Antioxidant, Endogenous,Antioxidants, Endogenous

Related Publications

Zhipei Sang, and Wanli Pan, and Keren Wang, and Qinge Ma, and Lintao Yu, and Yan Yang, and Ping Bai, and Chaoliang Leng, and Qian Xu, and Xiaoqing Li, and Zhenghuai Tan, and Wenmin Liu
April 2021, European journal of medicinal chemistry,
Zhipei Sang, and Wanli Pan, and Keren Wang, and Qinge Ma, and Lintao Yu, and Yan Yang, and Ping Bai, and Chaoliang Leng, and Qian Xu, and Xiaoqing Li, and Zhenghuai Tan, and Wenmin Liu
December 2022, Journal of enzyme inhibition and medicinal chemistry,
Zhipei Sang, and Wanli Pan, and Keren Wang, and Qinge Ma, and Lintao Yu, and Yan Yang, and Ping Bai, and Chaoliang Leng, and Qian Xu, and Xiaoqing Li, and Zhenghuai Tan, and Wenmin Liu
December 2019, European journal of medicinal chemistry,
Zhipei Sang, and Wanli Pan, and Keren Wang, and Qinge Ma, and Lintao Yu, and Yan Yang, and Ping Bai, and Chaoliang Leng, and Qian Xu, and Xiaoqing Li, and Zhenghuai Tan, and Wenmin Liu
February 2019, Chemical biology & drug design,
Zhipei Sang, and Wanli Pan, and Keren Wang, and Qinge Ma, and Lintao Yu, and Yan Yang, and Ping Bai, and Chaoliang Leng, and Qian Xu, and Xiaoqing Li, and Zhenghuai Tan, and Wenmin Liu
December 2023, Journal of enzyme inhibition and medicinal chemistry,
Zhipei Sang, and Wanli Pan, and Keren Wang, and Qinge Ma, and Lintao Yu, and Yan Yang, and Ping Bai, and Chaoliang Leng, and Qian Xu, and Xiaoqing Li, and Zhenghuai Tan, and Wenmin Liu
April 2014, European journal of medicinal chemistry,
Zhipei Sang, and Wanli Pan, and Keren Wang, and Qinge Ma, and Lintao Yu, and Yan Yang, and Ping Bai, and Chaoliang Leng, and Qian Xu, and Xiaoqing Li, and Zhenghuai Tan, and Wenmin Liu
July 2017, European journal of medicinal chemistry,
Zhipei Sang, and Wanli Pan, and Keren Wang, and Qinge Ma, and Lintao Yu, and Yan Yang, and Ping Bai, and Chaoliang Leng, and Qian Xu, and Xiaoqing Li, and Zhenghuai Tan, and Wenmin Liu
December 2022, ACS chemical neuroscience,
Zhipei Sang, and Wanli Pan, and Keren Wang, and Qinge Ma, and Lintao Yu, and Yan Yang, and Ping Bai, and Chaoliang Leng, and Qian Xu, and Xiaoqing Li, and Zhenghuai Tan, and Wenmin Liu
September 2019, European journal of medicinal chemistry,
Zhipei Sang, and Wanli Pan, and Keren Wang, and Qinge Ma, and Lintao Yu, and Yan Yang, and Ping Bai, and Chaoliang Leng, and Qian Xu, and Xiaoqing Li, and Zhenghuai Tan, and Wenmin Liu
March 2019, Bioorganic chemistry,
Copied contents to your clipboard!